世卫组织在全球认可减重药品,使人们对负担能力产生希望和关切。 WHO endorses weight-loss drugs globally, raising hopes and concerns over affordability.

世界卫生组织(世卫组织)准备核准全球成年人的减重药物,这一举动可能促进药品销售,但引起人们对可负担性的关切,在低收入国家尤其如此。 The World Health Organization (WHO) is set to endorse weight-loss drugs for adults globally, a move that could boost drug sales but raises concerns about affordability, especially in low-income countries. 这些药物,如Wegovy和Zepbound等,已经证明有助于使用者减少体重的15-20%,但每月费用超过1 000美元。 The drugs, such as Wegovy and Zepbound, have shown to help users lose 15-20% of their body weight but can cost over $1,000 per month. 如果将这些药品列入基本药品清单,卫生组织的支持可以使这些药品更容易获得,但费用仍然是一大障碍。 WHO's support could make these drugs more accessible if they are added to the essential medicines list, but cost remains a significant barrier.